HNMT and cancer: HMT inhibitors are reported as a key candidate for cancer therapies by recent preclinical studies.499 The administration of the lysine inhibitors tazemetostat, SHR2554, and pinometostat exhibited satisfactory therapeutic efficacy in several cancers with an acceptable safety profile.500 Further studies are still required to explore possible avenues for targeting metabolic memory in combination with cancer treatment.